Phase 1 Peripheral Neuropathy Trial, Recruiting NCT07140614 Sponsor: Novartis Pharmaceuticals Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 1 Peripheral Neuropathy Trial, Recruiting

NCT07140614
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form before any study assessments begin.
  • You are male or female and between 18 and 60 years old (inclusive) at the time of initial screening.
  • You have been formally diagnosed with Charcot-Marie-Tooth Disease Type 1A (CMT1A), confirmed by a certified genetic test showing a duplication of the PMP22 gene.
  • Nerve signal tests on at least one of your arms show detectable activity (either sensory or movement-related signals).
  • Your CMT1A symptom severity score (called CMTNSv2R) is between 3 and 20, confirmed at your baseline visit or recorded in your medical notes within the past 6 months.
  • You have measurable muscle weakness in foot/ankle lifting in at least one leg, confirmed at screening or recorded in your medical notes within the past 6 months.

Who may not be able to join:

  • You have difficulty communicating with the study team or would be unable to follow the study visits and procedures.
  • You have a history of heart, kidney, liver, blood, or immune system conditions.
  • You are pregnant or breastfeeding, or are a woman capable of becoming pregnant and not using a highly effective form of contraception throughout the study and follow-up period.
  • You are a sexually active male who is unwilling to use a condom during intercourse for the duration of the study.
  • You are unwilling or unable to provide a series of small skin samples (skin biopsies) as required by the study.
  • You are unwilling or unable to have repeated blood draws, or the study doctor believes these procedures would put you at increased risk.
  • You have taken any medication intended to treat or slow CMT1A in the 6 months before screening, including a combination drug called PTX-3003.
  • You have had a nerve injury caused by pressure or compression in the past 6 months, or you have another condition that can affect the nerves — such as diabetes, chronic heavy alcohol use, thyroid disease, certain infections, or past exposure to toxic substances or medications that can harm nerves.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-888-669-6682

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
25 February 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov